Rotavirus VP7 Specific Neutra™ Antibody Products

Are you currently facing challenges such as high viral mutation rates, difficulty in achieving high-titer neutralization in assays, or complex structural stabilization requirements for vaccine development? Our Rotavirus VP7 Specific Neutra™ Antibody Products help you develop highly specific therapeutic candidates and streamline clinical evaluation through innovative B-cell cloning and high-precision epitope-targeting technologies that stabilize the critical VP7 trimer.

Introduction of Rotavirus VP7

Rotavirus, a member of the Reoviridae family, remains a leading cause of severe, dehydrating diarrhea in infants and young children worldwide, contributing to approximately 200,000 deaths annually. The virus is a non-enveloped, triple-layered particle. The outermost layer is primarily composed of VP7 (Viral Protein 7), a 37-kDa calcium-binding glycoprotein, and the spike protein VP4.

Structure and Function

VP7 exists as a homotrimer on the virion surface, stabilized by two calcium ions at each subunit interface. Its primary biological function is to lock the VP4 spikes into place and maintain the structural integrity of the triple-layered particle (TLP). Once the virus enters the host cell endosome, the low calcium environment triggers the dissociation of the VP7 trimer. This "uncoating" event is a mandatory step for the release of the transcriptionally active double-layered particle (DLP) into the cytoplasm.

Signaling and Pathogenesis

VP7 interacts with host cell receptors, including integrins (e.g., α2β1 and αvβ3) and Hsc70, triggering PI3K/Akt and MAPK/ERK pathways to facilitate membrane penetration. Crucially, VP7-mediated calcium depletion from the ER activates sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) and induces autophagy via the CAMKKβ-AMPK pathway. This localized Ca²⁺ signaling also modulates NF-κB and interferon responses, creating a cellular environment conducive to viral replication and assembly.

The clinical impact is significant; rotavirus destroys mature enterocytes at the tips of the villi in the small intestine, leading to malabsorption and osmotic diarrhea. Furthermore, the non-structural protein NSP4 acts as a viral enterotoxin, further disrupting intracellular signaling and ion transport.

Fig.1 Rotavirus structure and replication cycle.¹

Clinical Relevance

VP7 defines the G-serotype (glycoprotein) of the virus. To date, at least 27 G-types have been identified, with G1, G2, G3, G4, and G9 being the most prevalent in human infections. Neutralizing antibodies targeting the epitopes on VP7 are a major correlate of protection against rotavirus disease, making it a primary focus for both live-attenuated and subunit vaccine strategies.

Applications of Anti-Rotavirus VP7 Neutralizing Antibodies

Anti-VP7 neutralizing antibodies serve as critical components in both diagnostic and therapeutic research frameworks:

• Neutralization Mechanism Studies: These antibodies are used to study the "cross-linking" mechanism, where the bivalent binding of the antibody stabilizes the VP7 trimer, preventing the necessary uncoating trigger even in low-calcium environments.
• Serotyping and Epidemiology: Utilizing serotype-specific nAbs allows for the precise classification of circulating rotavirus strains in clinical samples.
• Vaccine Potency Assays: They serve as positive controls in Microneutralization Assays to quantify the efficacy of new vaccine batches.
• Therapeutic Development: Research into passive immunization strategies often utilizes high-affinity anti-VP7 clones to prevent severe gastroenteritis in immunocompromised patients.

Our Anti-Rotavirus VP7 Specific Neutra™ Antibody Products

Creative Biolabs offers a premium selection of Neutra™ antibodies characterized by exceptional specificity and verified potency. Our portfolio includes:

• Serotype-Specific Monoclonal Antibodies: Highly selective clones targeting the 7-1a, 7-1b, and 7-2 epitope regions of VP7 for G1 through G12 serotypes.
• Cross-Reactive Neutra™ Antibodies: Clones designed to recognize conserved motifs across multiple G-types, providing broader research utility.
• Recombinant Humanized Versions: Facilitating the transition from preclinical models to therapeutic lead optimization.
• Custom Conjugations: Available with HRP, Biotin, or Fluorophores (FITC/PE) for advanced imaging and ELISA applications.

Our antibodies undergo rigorous quality control, including binding affinity measurements via Surface Plasmon Resonance (SPR) and functional neutralization titer verification against live rotavirus strains.

Creative Biolabs is dedicated to providing the global scientific community with high-performance Rotavirus VP7 Specific Neutra™ Antibody Products. Our combination of deep virology expertise and high-end manufacturing ensures that your drug discovery and diagnostic projects are supported by the most reliable reagents available.

For detailed product specifications, custom antibody development, or bulk inquiries, please reach out to our specialist team. We are ready to help you overcome your toughest research hurdles.

Reference

1. Papa, Guido et al. "Viroplasms: Assembly and Functions of Rotavirus Replication Factories." Viruses vol. 13,7 1349. 12 Jul. 2021, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/v13071349